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Abstract
Aim: To investigate the role of four parental folate
pathway single nucleotide polymorphisms (SNPs) i.e.,
methylene tetrahydrofolate reductase (MTHFR) 677C)T,
MTHFR 1298A)C, methionine synthase reductase (MTRR)
66A)G and glutamate carboxypeptidase (GCP) II
1561C)T on susceptibility to neural tube defects (NTDs) in
50 couples with NTD offspring and 80 couples with normal
pregnancy outcome.
Results: Maternal MTHFR 677C™T (odds ratio (OR): 2.69,
95% confidence interval (CI): 1.35–5.34) and parental GCP
II 1561C™T (maternal: OR: 1.89, 95% CI: 1.12–3.21 and
paternal: OR: 3.23, 95% CI: 1.76–5.93) were found to be
risk factors for a NTD. Both paternal and maternal GCP II
T-variant alleles were found to interact with MTHFR 677T-
and MTRR G-variant alleles in increasing the risk for NTD.
Segregation of data based on type of defect revealed an asso-
ciation between maternal 677T-allele and meningomyelocele
(OR: 9.00, 95% CI: 3.77–21.55, P-0.0001) and an associ-
ation between parental GCP II 1561T-allele and anencephaly
(maternal: OR: 2.25, 95% CI: 1.12–4.50, P-0.05 and pater-
nal: OR: 4.26, 95% CI: 2.01–9.09, P-0.001).
Conclusions: Maternal MTHFR C677T and parental
GCP II C1561T polymorphisms are associated with
increased risk for NTDs. Apart from individual genetic
effects, epistatic interactions were also observed.
Keywords: Glutamate carboxypeptidase (GCP) II; methio-
nine synthase reductase (MTRR); methylene tetrahydrofolate














High incidence of neural tube defects (NTDs) was observed
in South India w8x where consanguinity is common w7x and
vitamin deficiencies were reported w22x, which indicate the
role of genetic and nutritional factors as the possible etio-
logical factors specifically pointing towards folate metabo-
lism w9x. Hyperhomocysteinemia w12x and methylene
tetrahydrofolate reductase (MTHFR, MIM No: *607093)
C677T w19x and A1298C w18x polymorphisms are well-doc-
umented risk factors for NTD in other populations. Poly-
morphisms in cystathionine beta synthase (CBS, MIM No:
q236200) w11x, methytetrahydrofolate homocysteine methyl
transferase (MTR, MIM No: *156570) w3x and methionine
synthase reductase (MTRR, MIM No: *602568) w18x and
glutamate carboxypeptidase II (GCP II/FOLH1, MIM No:
*600934) w14x were also studied for possible association with
NTDs. However, data on GCP II are sparse. There are only
two studies from India, one projecting paternal hyperhomo-
cysteinemia and maternal folate deficiency as risk factors for
NTD w12x, whereas the other projecting MTHFR C677T
genetic polymorphism as a risk factor for NTD w4x. Neural
tube development occurs very early in fetal life prior to first
noticeable signs of pregnancy and post-conceptional folate
supplementation in such cases is not beneficial in reducing
the risk for NTDs. In developed countries, fortification of
foods with folic acid helped in reducing such risk whereas
in India there is no such public health measure and the genet-
ic risk factor profile might be different.
MTHFR is a rate-limiting enzyme in this pathway as its
activity determines the proportion of 5, 10-methylene tetra-
hydrofolate and 5-methyl tetrahydrofolate available for thy-
midylate synthesis and cellular methylation, respectively.
Two polymorphisms i.e., C677T and A1298C are widely dis-
tributed throughout the globe and reduce specific activity of
MTHFR differentially. The former polymorphism induces a
thermolabile variant enzyme whereas the later polymorphism
acts synergistically when co-segregated with the former.
GCP II, a folate hydrolase, hydrolyzes dietary folate (folyl
polyglutamates) to monoglutamates thus assisting in intesti-
nal absorption of folate. GCP II C1561T polymorphism
impairs intestinal absorption of folate especially when the
major source of folate is in polyglutamate form. MTRR is
an enzyme which helps in regeneration of inactive MTR by
reductive methylation of cobalamin. Cobalamin deficiency
coupled with MTR A66G polymorphism might significantly
impair re-methylation of homocysteine. The current study
was aimed to explore the role of these four folate pathway
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genetic polymorphisms i.e., MTHFR C677T, MTHFR
A1298C, MTRR A66G and GCP II C1561T in altering the
susceptibility to NTD in a South Indian cohort.
Subjects and methods
Fifty couples with an offspring with NTD were enrolled as cases.
The mean maternal and paternal age was 24.7 and 29.6 years,
respectively. Parental consanguinity was observed in 8% cases: 6%
were first cousins and 2% were uncle-niece marriages. These cou-
ples altogether had 103 pregnancies, 60 of which had a NTD. Infor-
mation about the type of defect was available for all cases: 26
(43.4%) anencephaly, 6 (10%) encephalocele, 28 (46.6%) spina bifi-
da w11 (18.3%) meningocele, and 17 (28.3%) meningomyelocelex.
Eighty maternal and 80 paternal controls were recruited for this
study. The mean maternal and paternal age was 24.3 and 28.9 years,
respectively. Parental consanguinity was observed in 10% of con-
trols: 7.5% were first cousins and 2.5% were uncle-niece marriages.
On the average these controls had 2–3 pregnancies and all preg-
nancies were normal. No history of any miscarriage or pregnancy
indicative of any congenital anomaly was observed. These controls
were of same ethnic group as the cases.
Neither cases nor controls were on pre- and peri-conceptional
folate supplementation of the indexed pregnancy. They have not
used any fortified food.
Subjects with IDDM, hypertension, chromosomal anomalies and
those on anti-folate medications were excluded from the study
group.
Informed consent was obtained from all subjects and ethical
clearance was obtained from the Ethical Committee of the Center
for DNA Fingerprinting and Diagnostics, Hyderabad, India.
Whole blood samples in EDTA were obtained from all subjects
and genomic DNA was isolated using standard protocols.
Genetic analyses
MTHFR 677C™T polymorphism A 173-bp band from exon 4
of MTHFR was amplified using specific primers i.e., 59-TTT GAG
GCT GAC CTG AAG CAC TTG AAG GAG-3 and 59-GAG TGG
TAG CCC TGG ATG GGA AAG ATC CCG-39. Each 25 ml of
PCR mixture was composed of 100 ng genomic DNA, 2.5 mL 10=
PCR buffer w50 mM KCl, 10 mM Tris-HCl (pH: 9.0), 1.5 mM Mg
Cl2x, 0.2 mM each of deoxynucleoside triphosphate, 10 pmol of
each primer and 1 unit of Taq DNA polymerase. The PCR condi-
tions were: initial denaturation, 958C for 5 min; denaturation,
958C for 1 min; annealing, 608C for 1 min; extension, 728C for
1 min; and number of cycles, 30. To test for the polymorphism,
20 mL of PCR product was digested with 1 unit of HinfI restriction
enzyme (recognition site: 59-GˆANTC-39) in 1X NEB buffer 2. Pres-
ence of MTHFR 677T-variant allele creates HinfI restriction site
causing cleavage of 173-bp product into 125-bp and 48-bp frag-
ments w6x.
MTHFR A™C polymorphism A 163-bp band from exon 7
of MTHFR was amplified using specific primers 59-CTT TGG GGA
GCT GAA GGA CTA CTA C-39 and 59-CAC TTT GTG ACC ATT
CCG GTT TG-39. Each 25 mL of PCR mixture was composed of
100 ng genomic DNA, 2.5 mL 10= PCR buffer w50 mM KCl,
10 mM Tris-HCl (pH: 9.0), 2.5 mM Mg Cl2x, 0.2 mM each of
deoxynucleoside triphosphate, 10 pmol of each primer and 1 unit
of Taq DNA polymerase. The PCR conditions were: initial dena-
turation, 958C for 5 min; denaturation, 958C for 1 min; annealing,
538C for 1 min; extension, 728C for 1 min; and number of cycles,
40. The PCR product was digested with MboII restriction enzyme
(recognition site: 59-GAAGA (N)8ˆ-39). 1298C-variant allele abol-
ishes one restriction site of MboII (84 bp, 31 bp, 30 bp, 18 bp)
whereas 1298A allele causes further cleavage (56 bp, 31 bp, 30 bp,
28 bp, 18 bp) w18x.
GCPII 1561C™T polymorphism A 244-bp band from exon 13
of GCP II was amplified using specific primers i.e., 59-CAT TCT
GGT AGG AAT TTA GCA-39 and 59-AAA CAC CAC CTA TGT
TTA ACA-39. Each 25 mL of PCR mixture was composed of 100 ng
genomic DNA, 2.5 mL 10= PCR buffer, 0.2 mM each of deoxy-
nucleoside triphosphate, 10 pmol of each primer and 1 unit of Taq
DNA polymerase. The PCR conditions were: initial denaturation,
958C for 5 min; denaturation, To test for the polymorphism, 20 mL
of PCR product was digested with 1 unit of AccI restriction enzyme
in 1X New England Biolabs (NEB) buffer 4. Presence of GCP II
1561T-variant allele creates AccI restriction site (59-GTˆMKAC-39)
causing cleavage of 244-bp product into 141-bp and 103-bp frag-
ments w5x.
MTRR 66A™G polymorphism Restriction digestion analysis
was performed with an artificially created NdeI restriction site using
the sense primer: 59-GCA AAG GCC ATC GCA GAA GAC AT-39
and antisense primer: 59-CAC TTC CCA ACC AAA ATT CTT
CAA AG- 39, where the underlined C replaces the A to generate an
NdeI restriction site (59-CAˆTATG-39) in the normal sequence. Each
25 mL of PCR mixture contained 100 ng DNA, 2 mL PCR buffer,
0.2 mM each of deoxynucleoside triphosphate, 10 pmol of each
primer, and 1 unit of Taq DNA polymerase. The PCR conditions
were: initial denaturation, 958C for 10 min; denatura-
tion, 958C for 1 min; annealing, 558C for 30 s; extension, 728C for
30 s; and number of cycles, 30. To test for the polymorphism, 20 mL
of PCR product was digested with 2 units of NdeI in 1=NEB buffer
4. The PCR fragment of 66-bp remains uncut in the presence of the
G (methionine) allele but is digested into fragments of 44-bp and
22-bp in the presence of the A (isoleucine) allele w14x.
Statistical analyses
Univariate analysis was carried out taking genotype frequencies and
allele frequencies as variables. Two-by-two contingency tables were
prepared for cases and controls based on presence or absence of
each variable. Frequencies, odds ratios (OR) and 95% confidence
intervals (CI) were calculated using Vassarstats software (http://
faculty.vassar.edu/lowry/VassarStats.html). Fisher exact test was
performed to obtain P-values. All statistical tests were based on two-
tailed probability and considered significant at P-0.05. Normal,
heterozygous and homozygous mutant genotypes were labeled as 0,
1 and 2, respectively based on number of mutated alleles and logis-
tic regression analysis was carried out to obtain P trend values. P
HWE values were obtained by x2-test for the observed frequencies
and expected frequencies according to Hardy–Weinberg equilibrium
test.
Bivariate analysis was done by computing the haplotype data in
y/y, y/q, q/y, q/q format where ‘‘y’’ indicates absence and
‘‘q’’ indicates presence of the mutated alleles. For pair-wise anal-
ysis, Fisher exact test was employed on each haplotype. Logistic
regression analysis for the four different haplotypes in cases and
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Table 1 Genotype/allele frequency distribution in couples with NTD and in couples with normal reproductive history.
SNP Genotypes Alleles OR (95% CI) P-value
Maternal
MTHFR C677T CC CT TT C T
Cases 33 11 6 77 23 2.69 (1.35–5.34) 0.008*
Controls 64 16 0 144 16
MTHFR A1298C AA AC CC A C
Cases 22 25 3 69 31 0.61 (0.36–1.03) 0.08
Controls 26 40 14 92 68
MTRR A66G GG AG AA G A
Cases 17 33 0 67 33 1.02 (0.60–1.74) 1.00
Controls 28 52 0 108 52
GCP II C1561T CC CT TT C T
Cases 9 41 0 59 41 1.89 (1.12–3.21) 0.03*
Controls 37 43 0 117 43
Paternal
MTHFR C677T CC CT TT C T
Cases 43 7 0 93 7 1.43 (0.52–3.93) 0.68
Controls 72 8 0 152 8
MTHFR A1298C AA AC CC A C
Cases 8 36 6 52 48 1.25 (0.76–2.06) 0.50
Controls 26 40 14 92 68
MTRR A66G GG AG AA G A
Cases 22 28 0 72 28 0.94 (0.54–1.62) 0.93
Controls 33 47 0 113 47
GCP II C1561T CC CT TT C T
Cases 16 34 0 66 34 3.23 (1.76–5.93) -0.0001*
Controls 58 22 0 138 22
*Statistically significant.
SNPssingle nucleotide polymorphisms, ORsodds ratio, CIsconfidence interval, GCPsglutamate carboxypeptidase, MTRRsmethionine
synthase reductase, MTHFRsmethylene tetrahydrofolate reductase, NTDsneutral tube defect.
controls was done to explore the possibility of gene-gene
interaction.
Results
Role of individual polymorphisms
Table 1 represents the distribution of genotypes and alleles
for individual polymorphisms in case and control couples.
MTHFR 677C™T Out of 50 NTD case mothers, 33 (66%)
were normal, 11 (22%) were heterozygous and 6 (12%) were
homozygous mutant for MTHFR 677C™T polymorphism.
Out of 80 control mothers, 64 (80%) were normal, 16 (20%)
were heterozygous and none were homozygous mutant. The
677T-allele frequencies were 23% and 10% in NTD case
mothers and control mothers, respectively. This variant allele
was associated with 2.7-fold risk for NTD.
Out of 50 NTD case fathers, 43 (86%) were normal, 7
(14%) were heterozygous and none were homozygous
mutant for this polymorphism. Out of 80 control fathers, 72
(90%) were normal, 8 (10%) were heterozygous and none
were homozygous mutant. The 677T-allele frequencies were
7% and 5% in NTD case fathers and control fathers, respec-
tively. This variant allele was not associated with any sig-
nificant risk for NTD.
MTHFR 1298A™C Out of 50 NTD case mothers, 22 (44%)
were normal, 25 (50%) were heterozygous and 3 (6%) were
homozygous mutant for MTHFR 1298A™C polymorphism.
Out of 80 control mothers, 26 (32.5%) were normal, 40
(50%) were heterozygous and 14 (17.5%) were homozygous
mutant. The 1298C-allele frequencies were 31% and 42.5%
in NTD case mothers and control mothers, respectively. This
variant allele was not associated with any significant risk for
NTD.
Out of 50 NTD case fathers, 8 (16%) were normal, 36
(72%) were heterozygous and 6 (12%) were homozygous
mutant. Out of the 80 control fathers, 26 (32.5%) were nor-
mal, 40 (50%) were heterozygous and 14 (17.5%) were
homozygous mutant. The 1298 C-allele frequencies were
48% and 42.5%, respectively in NTD case fathers and con-
trol fathers, respectively. This variant allele was not associ-
ated with any significant risk for NTD.
GCP II 1561C™T Out of 50 NTD case mothers, 9 (18%)
were normal, 41 (82%) were heterozygous and none were
homozygous mutant for GCP II 1561C™T polymorphism.
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Table 2 Bivariate analyses between different genotypes.
Gene-Gene interaction Combined Cases Controls OR (95% CI) P-value
genotype
Maternal
GCP 1561 MTHFR 677 C-C 6 21 Reference
C-T 3 16 0.66 (0.16–2.83) 0.88
T-C 27 43 2.20 (0.80–5.96) 0.20
T-T 14 0 Inf (10.87-Inf) -0.0001*
GCP 1561/MTRR 66 C-G 9 37 Reference
C-A 0 0 ND
T-G 41 43 3.92 (1.70–8.99) 0.002*
T-A 0 0 ND
MTHFR 677/MTRR 66 C-G 33 64 Reference
C-A 0 0 ND
T-G 17 16 2.06 (0.93–4.56) 0.12
T-A 0 0 ND
Paternal
GCP 1561/MTHFR 677 C-C 15 54 Reference
C-T 1 4 0.90 (0.13–6.64) 1.00
T-C 28 18 5.60 (2.47–12.68) -0.0001*
T-T 6 4 5.40 (1.43–20.31) 0.04*
GCP 1561/MTRR 66 C-G 16 58 Reference
C-A 0 0 ND
T-G 34 22 5.60 (2.61–12.04) -0.0001*
T-A 0 0 ND
MTHFR 677/MTRR 66 C-G 43 72 Reference
C-A 0 0 ND
T-G 7 8 1.47 (0.51–4.18) 0.67
T-A 0 0 ND
*Statistically significant.
Infsinfinite, ORsodds ratio, CIsconfidence interval, GCPsglutamate carboxypeptidase, MTRRsmethionine synthase reductase,
MTHFRsmethylene tetrahydrofolate reductase.
Out of 80 control mothers, 37 (46.25%) were normal, 43
(53.75%) were heterozygous and none were homozygous
mutant. The 1561T-allele frequencies were 41% and 26.9%
in NTD case mothers and control mothers, respectively. This
variant allele was associated with 1.9-fold risk for NTD.
Out of 50 NTD case fathers, 16 (32%) were normal, 34
(68%) were heterozygous and none were homozygous
mutant for this polymorphism. Out of 80 control fathers, 58
(72.5%) were normal, 22 (27.5%) were heterozygous and
none were homozygous mutant. The 1561T-allele frequen-
cies were 34% and 13.75% in NTD case fathers and control
fathers, respectively. This variant allele was associated with
3.2-fold risk for NTD.
MTRR 66A™G Out of 50 NTD case mothers, none were
normal, 33 (66%) were heterozygous and 17 (34%) were
homozygous mutant for MTRR 66A™G polymorphism. Out
of 80 control mothers, none were normal, 52 (65%) were
heterozygous and 28 (35%) were homozygous mutant. The
66G-allele frequencies were 67% and 67.5% in NTD case
mothers and control mothers, respectively. This variant allele
was not associated with any significant risk for NTD.
Out of 50 NTD case fathers, none were normal, 28 (56%)
were heterozygous and 22 (44%) were homozygous mutant
for this polymorphism. Out of 80 control fathers, none were
normal, 47 (58.75%) were heterozygous and 33 (41.25%)
were homozygous mutant. The 66G-allele frequencies were
72% and 70.62% in NTD case fathers and control fathers,
respectively.
Bivariate analysis
Pairwise analysis showed that 28% of NTD case mothers
had co-segregation of MTHFR 677T-GCP II 1561T-variant
alleles. None of the control mothers had this combination.
Co-segregation of GCP II 1561T-MTRR 66G-variant alleles
in mothers was associated with 3.9-fold risk for NTD. Co-
segregation of MTHFR 677T-MTRR 66 G-variant alleles
was not associated with statistically significant risk.
Paternal GCP II 1561T-MTRR 66G haplotype was asso-
ciated with 5.6-fold risk for NTD. MTHFR 677T-MTRR
66G haplotype was not associated with a significant risk
(Table 2).
Power calculations done for each statistically significant
association showed sufficient sample size (Table 3).
Segregation of data according to type of defect revealed
that maternal MTHFR 677T-varinat allele was associated
with 9-fold risk (95% CI: 3.77–21.55, P-0.0001) for menin-
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Table 3 Power calculations for statistically significant associations.
Genotype/alleles Estimated proportion Sample sizes(a: 0.05, power: 80%)
Cases Controls Required Actual
Maternal
MTHFR 677TT 0.12 0.00 77 130
GCP II 1561CT 0.82 0.54 50 130
MTHFR 677T-allele 0.23 0.10 142 260
GCP II 1561T-allele 0.41 0.27 193 260
GCP II 1561T-MTHFR 677T 0.28 0.00 30 130
GCP II 1561T-MTRR 66G 0.82 0.54 50 130
Paternal
GCP II 1561CT 0.68 0.28 29 130
GCP II 1561T-allele 0.34 0.14 81 260
GCP II 1561T-MTRR 66G 0.68 0.28 29 130
GCPsglutamate carboxypeptidase, MTRRsmethionine synthase reductase, MTHFRsmethylene tetrahydrofolate reductase.
gomyelocele. Maternal and paternal GCPII 1561T-variant
alleles were associated with 2.25- (95% CI: 1.12–4.50,
P-0.05) and 4.3 (95% CI: 2.01–9.09, P-0.001) fold
increased risk for anencephaly. No other statistically signif-
icant associations were observed between any other genotype
and type of NTD.
Discussion
The current study showed that maternal MTHFR C677T and
parental GCPII C1561T are genetically associated with NTD.
Bivariate analyses showed significant interactions between
MTHFR 677T/GCP II 1561T in mothers and GCP II 1561T/
MTRR 66G in both parents. Our study is in agreement with
the meta-analysis conducted by Botto and Yang, which
showed 1.75 folds (95% CI: 1.14, 2.18) increased risk for
NTD with MTHFR C677T polymorphism w2x. This study is
the first to project GCP II C1561T genetic polymorphism in
association to NTD. The risk associated with maternal
MTHFR 677TT genotype could be due to thermolabile var-
iant enzyme, which has enhanced propensity to dissociate
into inactive monomers with subsequent loss in FAD binding
capacity. This hampers the catalytic reduction of 5,10-meth-
ylene tetrahydrofolate to 5-methyl tetrahydrofolate, leading
to impaired methylation of homocysteine to methionine w23x.
The lack of risk associated with MTHFR 1298A™C poly-
morphism could be due to insignificant alteration in the spe-
cific activity of MTHFR as this polymorphism will not
induce thermolability and is there in regulatory domain of
the enzyme. The positive association with parental GCP II
1561C™T could be due to low folate status in the parents
as a result of impaired intestinal absorption of folates, which
will affect the placental folate transport (maternal) and might
induce sperm DNA damage (paternal). However, the role of
this polymorphism in reducing the intestinal absorption of
folate is still debated w1x.
Segregation of data according to genotype showed that
maternal MTHFR 677T-variant allele specifically increases
the risk for meningomyelocele whereas GCP II 1561T-vari-
ant allele (maternal/paternal) increases risk for anencephaly.
This might explain the failure of folic acid supplementation
to prevent all NTDs suggesting that the etiology of defect at
different sites might be different. Relton et al. have shown
that MTHFR C677T and GCP II C1561T-variants signifi-
cantly influence the risk of anencephalic pregnancy w13x
whereas Dalal et al. have shown that maternal MTHFR
C677T-variants significantly influence the risk for lower type
of defects i.e., spina bifida w4x.
Maternal MTHFR C677T and GCP II C1561T polymor-
phisms could result in significant depletion of functional
folate levels and significant increase in plasma homocysteine
levels, which affect the DNA synthesis and methylation pat-
tern of the fetus and provide toxic environment for the fetus
due to free radical generation as a result of auto-oxidation
of homocysteine w17x. Paternal GCP II C1561T polymor-
phism could induce sperm DNA damage due to reduced
folate availability for thymidylate synthesis thus increasing
uracil misincorporation in DNA or it increases the chances
of fetus inheriting this polymorphism especially when the
mother also has this polymorphism.
Parental MTRR 66A)G polymorphism alone was found
to have no impact on the risk for NTDs. However, co-seg-
regation of this polymorphism with GCP II 1561T-allele was
found to be associated with significant risk both maternally
and paternally. This shows strong evidence for epistatic inter-
action, where GCP II T-variant allele is acting as an epistatic
allele and MTRR G-variant allele is acting as a hypostatic
allele. The reason for such increased risk could be cumula-
tive effect of defective folate absorption and defective acti-
vation of cobalamin II to cobalamin I, which hampers
remethylation of homocysteine to methionine. This is con-
sistent with the study of Wilson et al. showing increased risk
for NTD in carriers of MTRR 66G allele when cobalamin
levels were low w21x, or in combination with MTHFR
677C)T mutant genotype. More recently Zhu et al. reported
an association between the G allele and NTD risk in a US
population w24x.
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Both maternal and paternal MTHFR 677T- and GCP II
1561T-variant alleles were found to have synergetic inter-
action in increasing the risk for NTD. The reason for such
synergetic effect could be cumulative effect of defective
folate absorption and defective synthesis of 5-methyl
tetrahydrofolate.
Lower availability of folate, 5-methyl tetrahydrofolate and
cobalamin (I) will result in low methionine synthesis, which,
in turn, affects the synthesis of universal methyl donor, S-
adenosyl methionine. During pregnancy, the requirement of
circulating folate and methionine increases significantly, as
maternal to fetal transport of these precursors is essential
during embryo development both for DNA synthesis and cel-
lular methylation w15x. These polymorphisms adversely
affect this process thereby resulting in hypomethylation.
Altered methylation profile of genes could have major con-
sequences during the neurulation phase in which gene
expression of the different genes involved in the closure of
the neural tube are following each other in a cascade event
w10x.
This study indicates significant gene-gene interactions
between different loci and thus, highlights the importance of
multiple loci in folate pathway for predicting the risk of
NTD. There is need to investigate gene-nutrient interactions
also for more precise risk prediction. The limitations of this
study are its sample size and lack of fetal/proband samples
to investigate maternal-fetal gene-gene interactions.
In summary, maternal MTHFR 677TT genotype and
parental GCPII 1561CT genotype were found to elevate the
risk for meningomyelocele and anencephaly, respectively, in
South Indian subjects. Significant gene-gene interactions
have been observed in the study group.MTHFR 677=GCPII
and GCPII=MTRR combinations in both parents were found
to significantly increase the risk for NTD in this population.
Parental genotype combinations in different folate pathway
loci seem to predict susceptibility for NTDs more precisely
than genotypes at individual loci. These data clearly empha-
size the need for multi-locus analyses in the risk prediction
of such multi-factorial disorders.
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